Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Glaukos (GKOS) Eyes +14% Advance Toward $280 on Execution Momentum

Glaukos (GKOS) Eyes +14% Advance Toward $280 on Execution Momentum

Key Takeaways

  • The $280 objective used here is not an analyst consensus; it is a fallback target drawn from publicly discussed bull-case and upper-bound forecasts (roughly $280–$284), not from the average of brokerage price targets.
  • The stock last traded near $245.72, so reaching $280 would require a gain of about 14%.
  • Among 11 recent 12-month analyst targets, the range was $210 to $255, with an arithmetic mean near $238 — already below the current price.
  • The four targets above the current price (Citi $247, H.C. Wainwright $248, Needham $251, Truist $255) average only about $250, well short of $280.
  • Key supports are surging sales of iDose TR and Epioxa, a raised 2026 outlook, and a preliminary $1 billion 2027 revenue target.
  • The biggest risks are Medicare coverage determinations, a demanding valuation, and heavy operating-expense growth.
  • Readers can track the latest Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
  • Explore Trending AI Robots to see AI-driven trading ideas across thousands of stocks and ETFs.

Why the $280 Target Stands Apart From Consensus

With GKOS now trading above the average analyst price target, the usual consensus approach no longer fits. A check of 11 recent 12-month targets shows a low of $210 from Jefferies and a high of $255 from Truist Financial, producing an arithmetic mean of roughly $238. The four targets still above the current price average only about $250, which is less than 2% above the market and well short of a 10% threshold. As a result, the $280 level draws instead from public market commentary on bull-case scenarios near $280 and upper-bound forecasts around $283–$284. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. This target is best viewed as valuation- and momentum-driven rather than a Street average.

Current Price Position and the Road to $280

GKOS last traded near $245.72, near the upper end of its 52-week range from roughly $73 to $255. Reaching $280 would imply about a 14% gain, a modest percentage move that would still require clearing all-time highs. Third-quarter revenue of $211 million rose 58% year over year, non-GAAP EPS of $0.47 beat estimates, and management lifted full-year 2026 revenue guidance to $775–$785 million while outlining a preliminary $1 billion sales goal for 2027. The stock already commands a high multiple of sales, so further gains will depend on earnings growth and multiple support rather than revenue alone.

Key Growth Drivers That Could Push Shares Higher

The main engines remain iDose TR, the long-duration glaucoma implant, and Epioxa, the first FDA-approved topical treatment for keratoconus. These products drove U.S. glaucoma sales up 47% and corneal health sales up 154% in the third quarter. Gross margin expanded to roughly 85% on a GAAP basis, and the company posted a small quarterly profit. Continued acceleration in these launches, broader reimbursement, and any upward analyst revisions would provide the clearest support for a move toward $280. From what I see, the operating momentum here is solid.

Potential Hurdles That Could Cap Upside

Medicare Administrative Contractors are evaluating local coverage determinations that might require patients to try laser treatment and two eye drops before iDose TR coverage, a step-therapy requirement management says is already factored into the $1 billion outlook but is still unresolved. Valuation remains stretched at roughly 13 times projected 2027 sales and a steep forward P/E. Operating expenses are expected to climb about 30% in 2026, and competition in ophthalmology, including the demodex blepharitis space, could pressure sentiment.

Technical Picture and Key Levels to Watch

The stock is consolidating just below record highs following a 30%-plus post-earnings rally. The prior all-time-high zone near $248–$255 now acts as the main resistance that needs to be cleared before $280 becomes realistic. On the downside, the pre-earnings breakout area near $210–$225 offers notable support. The long-term trend remains upward, yet the chart looks extended after more than a threefold rise from the 52-week low.

Time Frame and Items to Monitor Going Forward

Analyst targets generally span about 12 months, though the $280 level discussed publicly carries no formal deadline. Investors should watch quarterly iDose TR and Epioxa sales, fourth-quarter and 2027 guidance, any MAC coverage decisions on iDose TR, Epioxa reimbursement progress, operating-expense control, and analyst target changes. A downgrade or coverage setback could shift expectations quickly given the premium valuation. I’m watching this closely for any reimbursement updates.

Using Tickeron’s AI Daily Buy/Sell Signals for Ongoing Monitoring

In my own research process, Tickeron’s AI Daily Buy/Sell Signals have become a useful complement when tracking momentum in names like GKOS. The tool applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on shifting market conditions and technical factors. It helps surface potential turning points more efficiently than manual review alone, which is particularly helpful for volatile growth stocks where reimbursement news or earnings beats can move prices quickly. I find it keeps me informed without replacing independent judgment.

Final Assessment

Can GKOS reach $280? The level represents roughly a 14% advance from current prices and stems from public bull-case commentary rather than analyst consensus, which sits near $238 and below the market. The operating narrative—accelerating iDose TR and Epioxa sales, raised guidance, and a path to $1 billion in 2027 revenue—remains genuinely strong. On the other side, a premium valuation, open Medicare coverage questions, and rising spending leave little margin for disappointment. Whether the stock gets there will likely depend on reimbursement clarity and continued beat-and-raise execution rather than the rally already in place.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GKOS

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


GKOS saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for GKOS moved out of overbought territory on November 18, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 71 similar instances where the indicator exited the overbought zone. In 53 of the 71 cases the stock moved lower. This puts the odds of a downward move at 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for GKOS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 30 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GKOS as a result. In 63 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.

The Moving Average Convergence Divergence Histogram (MACD) for GKOS turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In 39 of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

GKOS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +8.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

The Aroon Indicator entered an Uptrend today. In 242 of 314 cases where GKOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 15 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.395) is normal, around the industry mean (4.142). P/E Ratio (-68.627) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -16%. POAS experienced the highest price growth at 158%, while LFWD experienced the biggest fall at -44%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 63
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an ophthalmic medical device company

Industry MedicalNursingServices

Industry
Medical Specialties
Address
One Glaukos Way
Phone
+1 949 367-9600
Employees
1094
Web
https://www.glaukos.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.